Cover Image
市場調查報告書

Oncomatryx Biopharma, S.L.- 產品平台分析

Oncomatryx Biopharma, S.L. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 351254
出版日期 內容資訊 英文 24 Pages
訂單完成後即時交付
價格
Back to Top
Oncomatryx Biopharma, S.L.- 產品平台分析 Oncomatryx Biopharma, S.L. - Product Pipeline Review - 2015
出版日期: 2015年12月30日 內容資訊: 英文 24 Pages
簡介

Oncomatryx Biopharma, S.L.是總公司設立於西班牙的生物科技企業,正在開發治療用抗體,抗體藥物複合體,人類蛋白質等,以腫瘤環境內蛋白質為標的的個體化醫療之新藥物。

本報告提供Oncomatryx Biopharma, S.L.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Oncomatryx Biopharma, S.L.的基本資料

  • Oncomatryx Biopharma, S.L.概要
  • 主要資訊
  • 企業資料

Oncomatryx Biopharma, S.L.:R&D概要

  • 主要的治療範圍

Oncomatryx Biopharma, S.L.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Oncomatryx Biopharma, S.L.:開發中產品概況

  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Oncomatryx Biopharma, S.L.:藥物簡介

  • OMTX-001
  • OMTX-503
  • OMTX-505
  • OMTX-705
  • OMTX-007
  • OMTX-703

Oncomatryx Biopharma, S.L.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Oncomatryx Biopharma, S.L.:暫停開發中的計劃

Oncomatryx Biopharma, S.L.:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

目錄
Product Code: GMDHC07947CDB

Summary

Global Markets Direct's, 'Oncomatryx Biopharma, S.L. - Product Pipeline Review - 2015', provides an overview of the Oncomatryx Biopharma, S.L.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Oncomatryx Biopharma, S.L.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Oncomatryx Biopharma, S.L. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Oncomatryx Biopharma, S.L.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Oncomatryx Biopharma, S.L.'s pipeline products

Reasons to buy

  • Evaluate Oncomatryx Biopharma, S.L.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Oncomatryx Biopharma, S.L. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Oncomatryx Biopharma, S.L.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Oncomatryx Biopharma, S.L. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Oncomatryx Biopharma, S.L.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Oncomatryx Biopharma, S.L. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Oncomatryx Biopharma, S.L. Snapshot
    • Oncomatryx Biopharma, S.L. Overview
    • Key Information
    • Key Facts
  • Oncomatryx Biopharma, S.L. - Research and Development Overview
    • Key Therapeutic Areas
  • Oncomatryx Biopharma, S.L. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Oncomatryx Biopharma, S.L. - Pipeline Products Glance
    • Oncomatryx Biopharma, S.L. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Oncomatryx Biopharma, S.L. - Drug Profiles
    • OMTX-001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OMTX-503
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OMTX-505
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OMTX-705
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OMTX-007
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OMTX-703
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Oncomatryx Biopharma, S.L. - Pipeline Analysis
  • Oncomatryx Biopharma, S.L. - Pipeline Products by Target
  • Oncomatryx Biopharma, S.L. - Pipeline Products by Molecule Type
  • Oncomatryx Biopharma, S.L. - Pipeline Products by Mechanism of Action
  • Oncomatryx Biopharma, S.L. - Dormant Projects
  • Oncomatryx Biopharma, S.L. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Oncomatryx Biopharma, S.L., Key Information
  • Oncomatryx Biopharma, S.L., Key Facts
  • Oncomatryx Biopharma, S.L. - Pipeline by Indication, 2015
  • Oncomatryx Biopharma, S.L. - Pipeline by Stage of Development, 2015
  • Oncomatryx Biopharma, S.L. - Monotherapy Products in Pipeline, 2015
  • Oncomatryx Biopharma, S.L. - Preclinical, 2015
  • Oncomatryx Biopharma, S.L. - Discovery, 2015
  • Oncomatryx Biopharma, S.L. - Pipeline by Target, 2015
  • Oncomatryx Biopharma, S.L. - Pipeline by Molecule Type, 2015
  • Oncomatryx Biopharma, S.L. - Pipeline Products by Mechanism of Action, 2015
  • Oncomatryx Biopharma, S.L. - Dormant Developmental Projects,2015

List of Figures

  • Oncomatryx Biopharma, S.L. - Pipeline by Top 10 Indication, 2015
  • Oncomatryx Biopharma, S.L. - Pipeline by Stage of Development, 2015
  • Oncomatryx Biopharma, S.L. - Monotherapy Products in Pipeline, 2015
  • Oncomatryx Biopharma, S.L. - Pipeline by Top 10 Target, 2015
  • Oncomatryx Biopharma, S.L. - Pipeline by Top 10 Molecule Type, 2015
  • Oncomatryx Biopharma, S.L. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top